Efficacy of adjunctive mitochondrial modulators for bipolar depression: A comprehensive systematic review and network meta-analysis.
Tzu-Rong Peng, Ming-Chia Lee, Kazuto Isuzugawa et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis compared adjunctive mitochondrial modulators for depressive symptoms in adults with bipolar depression, using evidence from 22 double-blind randomised controlled trials. Coenzyme Q10 (CoQ10) and N-acetylcysteine (NAC) had the most favourable estimates versus placebo: CoQ10 showed a large effect (SMD = -1.14, 95% CI: -2.09 to -0.19), based on a single trial, while NAC showed a moderate effect (SMD = -0.37, 95% CI: -0.74 to -0.01). The authors considered the findings preliminary because evidence certainty was limited and active treatments lacked direct comparisons.
Key findings
- CoQ10 significantly outperformed placebo (SMD = -1.14, 95% CI: -2.09 to -0.19), but the estimate came from a single trial.
- NAC, evaluated in 8 trials, showed a significant moderate effect versus placebo (SMD = -0.37, 95% CI: -0.74 to -0.01).
- The remaining 10 modulators showed no statistically significant differences from placebo.
- The network had no direct head-to-head comparisons among active treatments; certainty was moderate for agomelatine and low to very low for the other interventions, including CoQ10.
Why it matters
Adjunctive options for bipolar depression have limitations, and this analysis identifies CoQ10 and NAC as candidates with favourable relative efficacy estimates. However, network rankings rely on indirect comparisons, and the evidence does not establish that either agent is superior to other active treatments. The results help frame research priorities but should not be interpreted as definitive comparative evidence.
What to keep in mind
The network contained no direct comparisons between active treatments. CoQ10 evidence came from a single trial, and certainty was low to very low for most interventions.